Life science current events will collide with political realities in Minnesota. Last year the medical industry made important strides, including winning an angel investment tax credit. This year healthcare interests will likely be on the defensive. The University of Minnesota, the Biomedical Discovery District and health services for the poor are on the chopping block.
The University of Minnesota said its scientists have discovered a possible way to stop the spread of the virus that causes AIDS by preventing the pathogen from attaching itself to an antiviral protein. APOBEC3F belongs to a family of proteins that defend the body against viruses. The HIV virus, however, has developed an ability to attach itself to the protein and destroy it.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
The University of Minnesota said Wednesday that scientists have established a firm relationship between a protein known as tau and Alzheimer’s disease, the most common form of elderly dementia in the United States. In a study published in the journal Neuron, researchers say that an early buildup of tau in the dendritic spines, a region […]
A group of University of Minnesota professors want the board of regents to investigate the suicide of a patient enrolled in a university-run drug study. the professors demand the regents appoint an independent outside panel of experts to examine potential ethics violations in the death of Dan Markingson, a mentally ill patient who killed himself after taking an experimental psychiatric drug developed by AstraZeneca.
Orasi Medical Inc., a University of Minnesota-bred software startup that is developing software designed to help pharmaceuticals makers speed the development of drugs targeting neurological diseases, like Alzheimer's, has raised $1.8 million from the sale of equity. Overall, the company hopes to raise $2.6 million by December.
Eric Kaler, a chemical engineer expert who is provost of SUNY's Stony Brook University, is the sole candidate to replace outgoing University of Minnesota president Robert Bruininks, the Board of Regents said Friday.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Dr. Frank Cerra has hitched his wagon to outgoing University of Minnesota president Robert Bruininks. Cerra, medical school dean and head of the school's Academic Health Center, is retiring at the end of the year partly because Bruininks is doing the same. It's just as well. Together, the two men had sought to remake the school into a top research university and an economic engine for Minnesota. But as they prepare to exit, their vision is in doubt.
Medical device firms have good reason to dislike the healthcare reform law. You would, too, if Uncle Sam taxed you $20 billion to pay for it. The industry warned the tax would crush innovation, especially for startups that can't afford it. But tucked away in the law is a little-known tax credit designed to help those very companies.
The University of Minnesota said Thursday its scientists may have identified an area of the brain that indicates a patient suffers from post traumatic stress disorder (PTSD). Using a relatively new imaging technique called magnetoencephalography (MEG), researchers at the medical school and the Minneapolis Veteran Affairs Medical Center detected hyper electrical activity in the right side of the brain of PTSD patients who experienced involuntary flashbacks commonly associated with the disorder.
When Mike Selzer first reviewed the work of University of Minnesota scientist Dr.Erik Cressman -- a way to kill cancer cells in the liver using chemical-generated heat -- the veteran medical device executive was impressed. Cool technology, he thought. Terrible idea for a company.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
In launching Decade of Discovery, a $250 million-to-$350 million diabetes partnership, the University of Minnesota and Mayo Clinic are opting for an approach that requires the help of virtually everyone with a stake in Minnesota's healthcare economy: hospitals, payers, food manufacturers, device companies, biotech startups.
The University of Minnesota has licensed a test for lupus to Laboratory Corporation of America Holdings (NYSE:LH). Developed by Emily Baechler Gillespie, an assistant professor of medicine at the university's medical school, the test can help doctors proactively treat symptoms of lupus, a painful autoimmune disease.
There is a (gradual) changing of the guard at the University of Minnesota's Venture Center. Beginning last July, director Doug Johnson trimmed his work schedule to three days a week, allowing associate director Russ Straate to assume more responsibilities.
Sometimes, things just come together. On Friday, American Diabetes Association (ADA) CEO Larry Hausner gave the keynote address to LifeScience Alley's Diabetes Leadership Roundtable. Hausner was in town for the ADA conference in Minneapolis. As it happens, the University of Minnesota and Mayo Clinic last week launched a ten year, $250 million-to-$350 million partnership to cure diabetes. Not to be outdone, New York City Mayor Michael Bloomberg also announced a plan to combat obesity by banning city residents from using food stamps to purchase sodas. An attendee at the diabetes round table asked Hausner what he thought of Bloomberg's plan. "Well...that's a real political issue," Hausner answered carefully.
It's diabetes or bust. The University of Minnesota and Mayo Clinic are betting Minnesota's economic future on treating and even curing diabetes, the leading cause of death in the United States. Dubbed Decade of Discovery, the partnership between the state's two top research institutions will seek $250 million to $350 million over the next ten years to fund clinical research, public health initiatives and efforts that convert promising technologies into companies and industries.